|
"[A]
method for preventing and fighting the harmful biological effects
of free radicals...namely...inflammation...[and] collagen
degradation"
- U.S. Patent 4,698,360 inventor, Dr. Jack Masquelier.
Flavay™ can have a dramatic,
visible effect on your skin. The nutrients in Flavay™ can be
considered as 'collagen vitamins' because they partake in the
biosynthesis of collagen and prevent its destruction. Through
synergistic action with vitamin C, Flavay™ strengthens and
rebuilds the body’s natural collagen proteins and has the
remarkable ability to reactivate damaged collagen and elastin.
Research has demonstrated that Flavay™ binds to collagen fibers
and realigns them to a more youthful, undamaged form. (The same
research also established that common bioflavonoids are completely
inactive in this respect.)
Laboratory
tests
have demonstrated
Flavay’s™ ability to
reduce degradation of elastin fibers by up to
70 percent.
|
Flavay™ improves the beneficial
cross-linking between the amino acids of the fibers that give skin
its flexibility and strength while preventing the undesirable
cross-linking between amino acids that ages skin like leather.
Laboratory tests have demonstrated Flavay’s™
ability to reduce degradation of elastin fibers by up to 70
percent.
Flavay’s™ ability to
reactivate damaged collagen and elastin has great implications for
all of your body’s organs. Collagen is required for the normal
functioning of the joints, healthy cartilage and bones, smooth
gliding surfaces, synovial fluid, normal joint spaces and normal
soft tissues surrounding the joints. Collagen is the building
block of connective tissue, veins, arteries, ligaments and
tendons, and every tissue and organ.
Flavay™
Improves Circulation to Skin Cells
Flavay™
strengthens collagen in vessel walls and capillaries—
resulting in radiant and more youthful skin.
|
Improved circulation is another
reason that Flavay™ is an important part of optimally nourishing
your skin. Over 50 years of scientific and clinical research
establishes that Flavay™ actually strengthens collagen in
vascular walls and capillaries (the smallest vessels) by making
the vessels stronger and more elastic. As we age, the tiny
capillaries begin to break down, resulting in diminished blood
flow. Fortifying these tiny blood vessels will improve circulation
throughout the body, including the skin, delivering blood and
nutrients to your skin. Improved circulation results in
well-nourished, healthy skin—which is radiant and more youthful.
Inflammations
and Edema (Swelling)
Flavay™ has been licensed and
sold in France for treating edema and inflammations since 1950.
Puffiness of the eyes and an overall bloated look and feel are
examples of edema. It involves the leakage of blood serum into
surrounding tissues and Flavay™ has shown that it can reduce
this leakage by strengthening capillary walls.
Flavay™
inhibits the release and synthesis of histamine—a key
factor in the promotion of inflammation.
|
One of the very first benefits
observed and studied by the inventor of Flavay™, Dr. Jack
Masquelier, in as early as 1947, was its anti-inflammatory effect.
His and others' research demonstrated that Flavay™ inhibits the
release and synthesis of histamine (which produces accelerated
blood flow, dilates capillaries and increases their permeability,
thereby leaking plasma into surrounding tissue), a key factor in
the promotion of inflammation. Numerous studies have demonstrated
that the anti-histamine action of Flavay™ is obtained through
inhibiting the activity of the enzyme histidine decarboxylase.
Research shows that Flavay™ may lower the production of
histamine with as much as 86% inhibition of histidine
decarboxylase.
In an Australian study conducted
on two groups of soccer players that had sustained injuries, those
that consumed Flavay™ for ten days following their injuries
experienced significantly less swelling than those who did not
and, in some of those taking Flavay™, the swelling had
completely disappeared. Other research has demonstrated the ways
in which Flavay™ may actually inhibit inflammation including
double-blind studies conducted in France which showed that Flavay™
can reduce postoperative inflammation.
Proven
Safety of Flavay™
After more than 50 years of human
use, no adverse effects have been observed. Furthermore, intensive
biological, toxicological, pharmacological and analytical research
was conducted for the purpose of registering it as a medicine in
France and other countries in Europe. In one study, daily doses of
up to 35,000 mg for six months were determined to cause no adverse
effects. Flavay™ was also clinically tested, in particular for
all sorts of symptoms related to venolymphatic insufficiencies (strenghthening
veins, improving circulation and reducing edema and
inflammations). The spin-off is a goldmine of data: The rigorous
testing to meet the standards required by the health ministries of
France, Germany and other European countries demonstrate that
Flavay™ is highly bioavailable, nontoxic, nonallergenic,
noncarcinogenic, nonmutagenic, will not cause birth defects, and
is completely safe.
Dr. Masquelier’s unequaled
manufacturing process has been conducted for half a century at the
very same facilities in France, and under the control of French
Pharmaceutical inspection. These time-proven standards serve as a
reliable assurance of the quality, consistency, bioavailability
and safety of Flavay™.
Who
can take Flavay™?
Everyone, from the very young to
elderly. Flavay™ has no known contraindications (conditions
under which it should not be used). Flavay™ is completely safe
and nontoxic. In fact, clinical trials have been conducted in
which pregnant women (troubled by varicose veins and other
circulatory problems in the legs) safely used Flavay™.
Why
Trust Flavay™
Consumers need to know that the
marketplace is full of imitations, various “extracts” and
derivative forms of Dr. Masquelier’s scientifically proven and
patented complex. Unfortunately, many have even used Dr.
Masquelier’s name and research in unauthorized ways to promote
illegitimate products.
Flavay™ is the name you can
trust for the precisely defined active polyphenol complex patented
and perfected by the inventor, Dr. Jack Masquelier, validated by
the French Ministry of Health and documented by a library of
research consisting of many patents and hundreds of scientific
papers, articles, doctorate theses, lectures and presentations.
For quality, consistency, bioavailablity and safety, consumers may
rely upon Flavay™.
Flavay™
Improves the Health and Appearance of Skin
Flavay™
is the amazing internal cosmetic, improving the health and
appearance of the skin from the inside out: rebuilding collagen,
improving circulation and health in skin cells, and reducing
inflammation.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top
|
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa Omega Editrice,
Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers,
1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Mindell, E., et al. Earl Mindells vitamin bible for the 21st century.
Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Lieberman, S., et al. The real vitamin & mineral book: going beyond
the RDA. Avery Pub., 1990.
__ , Based on the results of this controlled study of men with heart disease,
the authors conclude that vitamin B-6 deficiency may influence vascular
connective tissue and thrombogensis (clotting). Atherosclerosis 55 (Ju 1985):
357-361.
__ , Experiments giving animals diets deficient in vitamin B-6 have resulted
in an enhanced risk of cardiovascular disease and other experiments suggest
the same may be true in humans. Medical Hypotheses 15 (De 1984):361-367.
__ , Low levels of vitamin B-6 my increase the risk of heart attack. American
Journal of Cardiology 63 (1989): 513-516.
Carper, J., The miracle heart. HarperCollins Publishers, 2000.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de laction des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii lattachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3,
4.4, 5.7-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, Free radicals in biotechnology
and medicine. Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease.
Cambridge University Press, 1997.
Libby, P., Ridker, P.M., Maseri, A. Inflammation and atherosclerosis. Circulation
2002 Mar 5; 105(9): 1135-43.
Lindahl, B. et al. Markers of myocardial damage and inflammation in relation
to long-term mortality in unstable coronary artery disease. FRISC Study
Group. Fragmin during Instability in Coronary Artery Disease. N. Engl. J.
Med. 2000 Oct 19; 343(16): 1139 47.
Mendall, M.A., et al. In the largest study of its kind published to date,
researchers report that hospitalized heart patients who took antibiotics
had a significantly lower risk of returning to the hospital with severe
chest pain within one year compared with those on a placebo. Circulation:
Journal of the American Heart Association, Aug. 20, 2002.
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N. Engl. J. Med. 1997 Apr 3; 336(14): 973-9.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted
from vitus vinifera l. in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez lanimal-activite aniagoniste vis-a-vis des mediateurs de linflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par laction dune substance
capillaro-toxique chez des personnes agees--action benefique dun agnet
actif sur la micro-circulation: lEndotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude dun
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand lhypertension arterielle
et certaines nephropathies. Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique dun angioprotecteur
peripherique,
lEndotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de lEndotelon sur lindice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur lEndotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de lEndotelon dans linsuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de lEndotelon dand les manifestations
fonctionnelles de linsuffisance veineuse peripherique-resultats dune
etude en double aveugle portant sur 92 patients. Gazette Medicale,
(92)1, 1985. pp. 96-100.
Wegrowski, J., Robert, A.M., Maczar, M. The effect of procyanidolic oligomers
on the composition of normal and hypercholesterolemic rabbit aortas.
Biochem. Pharmacol, (33)21. 1984. pp. 3491-3497.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. Les procyanidols du vin leur role dans lalcoolisme.
pp. 88-93.
Gazave, J.M. Notions recentes sur les capillaires
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of
procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur lhyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P Une Etude Exemplaire Pour Un
Phlebotrope: letude EIVE. Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. Collagen treated with (+)
-catechin becomes resistant to the action of mammalian
collagenase.
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat. Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr.
Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy, G.M. Etude d lEndotelon en
opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et
O.P.C. Bordeaux Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas. Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a letude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica,
9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur lulcere gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIERs®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members
superieurs. Symposium Satellite, Congres International dAngiologie,
Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks
of intense training. Abstract submitted to national meeting of the Amer
College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by
chronic phosphatidylserine administration of the stress-induced activation
of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm
43: 385388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced overtraining.
Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur loxydation
de lacide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur lacide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka,
I. Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells. Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro. Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. Les oedemes post-traumatoqies
chez le sportif: essai controle de lEndothelon. Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. Flavonoids et Pycnogenols Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990.
Cheon, B.S.; Kim, Y.H.; Son, K.S.; Wook Chang, H; Sik Kang, S.; Pyo Kim,
H. Planta. Med., 2000, 66, 596.
Virgili, F.; Kim, D.; Packer, L. FEBS Lett., 1998, 431, 315.
Kim, H.K.; Cheon, B.S.; Kim, Y.H.; Kim, S.Y.; Kim, H.P. Biochem. Pharmacol.,
1999, 58, 759.
Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all brain functions
and counters Alzheimers disease: Keats Pub. 1998.
Cenacchi T, et al. Cognitive decline in the elderly: A double-blind, placebo-controlled
multicenter study on efficacy of phosphatidylserine administration. Aging,
5: 123133, 1993.
Maggioni M, Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine
therapy in geriatric patients with depressive disorders. Acta Psychiatr
Scand. 81: 265270, 1990.
Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration
in peripheral blood mononuclear cells of elderly depressed patientseffects
of phosphatidylserine therapy. Neuropsychobiology, 34: 1821, 1996.
Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic
phosphatidylserine administration of the stress-induced activation of the
hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43:
385388, 1992.
Cenacchi T, et al., Cognitive decline in the elderly: A double-blind,
placebo-controlled multicenter study on efficacy of phosphatidylserine administration.
Aging, 5, 123-133, 1993
Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G.
Double-blind study with phosphatidylserine in parkinsonian patients with
senile dementia of Alzheimers type (SDAT). Prog Clin Biol Res, 317:1235-46,
1989. |
|